Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

Kristi McIntyre; Joyce O’Shaughnessy; Lee Schwartzberg; Stefan Glück; Erhan Berrak; James X. Song; David Cox; Linda T. Vahdat

doi:10.1007/s10549-014-2923-9

Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-014-2923-9 ◽

2014 ◽

Vol 146 (2) ◽

pp. 321-328 ◽

Cited By ~ 32

Author(s):

Kristi McIntyre ◽

Joyce O’Shaughnessy ◽

Lee Schwartzberg ◽

Stefan Glück ◽

Erhan Berrak ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor Receptor ◽

Phase 2 ◽

First Line ◽

Eribulin Mesylate ◽

First Line Therapy ◽

Line Therapy ◽

Phase 2 Study ◽

Epidermal Growth ◽

Locally Recurrent

Download Full-text

Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-014-3010-y ◽

2014 ◽

Vol 146 (2) ◽

pp. 329-329 ◽

Cited By ~ 1

Author(s):

Kristi McIntyre ◽

Joyce O’Shaughnessy ◽

Lee Schwartzberg ◽

Stefan Glück ◽

Erhan Berrak ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor Receptor ◽

Phase 2 ◽

First Line ◽

Eribulin Mesylate ◽

First Line Therapy ◽

Line Therapy ◽

Phase 2 Study ◽

Epidermal Growth ◽

Locally Recurrent

Download Full-text

Abstract P3-13-05: Eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer: Results of a phase 2, multicenter, single-arm study

10.1158/0008-5472.sabcs13-p3-13-05 ◽

2013 ◽

Author(s):

K McIntyre ◽

J O'Shaughnessy ◽

L Schwartzberg ◽

S Glück ◽

E Berrak ◽

...

Keyword(s):

Breast Cancer ◽

Phase 2 ◽

First Line ◽

Eribulin Mesylate ◽

First Line Therapy ◽

Line Therapy ◽

Locally Recurrent

Download Full-text

Abstract P1-12-02: Results of a phase 2, multicenter, single-arm study of eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer

10.1158/0008-5472.sabcs12-p1-12-02 ◽

2012 ◽

Cited By ~ 1

Author(s):

L Vahdat ◽

L Schwartzberg ◽

S Glück ◽

J Rege ◽

J Liao ◽

...

Keyword(s):

Breast Cancer ◽

Phase 2 ◽

First Line ◽

Eribulin Mesylate ◽

First Line Therapy ◽

Line Therapy ◽

Locally Recurrent

Download Full-text

Abstract P5-17-03: Quality of life results from a phase 2, multicenter, single-arm study of eribulin mesylate plus trastuzumab as first-line therapy for locally recurrent or metastatic HER2+ breast cancer

10.1158/1538-7445.sabcs14-p5-17-03 ◽

2015 ◽

Author(s):

Lee Schwartzberg ◽

Sharon Wilks ◽

Shannon Puhalla ◽

Joyce O'Shaughnessy ◽

Erhan Berrak ◽

...

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Phase 2 ◽

First Line ◽

Eribulin Mesylate ◽

First Line Therapy ◽

Her2 Breast Cancer ◽

Line Therapy ◽

Locally Recurrent

Download Full-text

Abstract P4-12-12: Phase 2, multicenter, single-arm study of eribulin mesylate + trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer

10.1158/0008-5472.sabcs13-p4-12-12 ◽

2013 ◽

Cited By ~ 1

Author(s):

S Wilks ◽

S Puhalla ◽

J O'Shaughnessy ◽

L Schwartzberg ◽

E Berrak ◽

...

Keyword(s):

Breast Cancer ◽

Phase 2 ◽

First Line ◽

Her2 Positive ◽

Eribulin Mesylate ◽

Her2 Positive Breast Cancer ◽

First Line Therapy ◽

Line Therapy ◽

Locally Recurrent ◽

Positive Breast Cancer

Download Full-text

Abstract P5-20-04: Eribulin mesylate + trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer: results from a phase 2, multicenter, single-arm study

10.1158/0008-5472.sabcs12-p5-20-04 ◽

2012 ◽

Cited By ~ 2

Author(s):

L Vahdat ◽

L Schwartzberg ◽

S Wilks ◽

J Rege ◽

J Liao ◽

...

Keyword(s):

Breast Cancer ◽

Phase 2 ◽

First Line ◽

Her2 Positive ◽

Eribulin Mesylate ◽

Her2 Positive Breast Cancer ◽

First Line Therapy ◽

Line Therapy ◽

Locally Recurrent ◽

Positive Breast Cancer

Download Full-text

Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2014.04.004 ◽

2014 ◽

Vol 14 (6) ◽

pp. 405-412 ◽

Cited By ~ 32

Author(s):

Sharon Wilks ◽

Shannon Puhalla ◽

Joyce O'Shaughnessy ◽

Lee Schwartzberg ◽

Erhan Berrak ◽

...

Keyword(s):

Breast Cancer ◽

Phase 2 ◽

First Line ◽

Her2 Positive ◽

Eribulin Mesylate ◽

Her2 Positive Breast Cancer ◽

First Line Therapy ◽

Line Therapy ◽

Locally Recurrent ◽

Positive Breast Cancer

Download Full-text

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

Breast Cancer Research and Treatment ◽

10.1007/s10549-018-05125-4 ◽

2019 ◽

Vol 174 (3) ◽

pp. 719-729 ◽

Cited By ~ 56

Author(s):

H. S. Rugo ◽

R. S. Finn ◽

V. Diéras ◽

J. Ettl ◽

O. Lipatov ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Epidermal Growth Factor Receptor ◽

Growth Factor Receptor ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Estrogen Receptor Positive ◽

Epidermal Growth

Download Full-text

Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study

Cancer ◽

10.1002/cncr.30170 ◽

2016 ◽

Vol 122 (20) ◽

pp. 3119-3126 ◽

Cited By ~ 8

Author(s):

Jean-Marc Ferrero ◽

Anne-Claire Hardy-Bessard ◽

Olivier Capitain ◽

Alain Lortholary ◽

Bruno Salles ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Triple Negative ◽

Locally Advanced Breast Cancer ◽

Locally Advanced ◽

Phase 2 ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Phase 2 Study

Download Full-text

Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study

The Breast ◽

10.1016/j.breast.2014.11.003 ◽

2015 ◽

Vol 24 (3) ◽

pp. 182-190 ◽

Cited By ~ 32

Author(s):

Véronique Diéras ◽

Hans Wildiers ◽

Jacek Jassem ◽

Luc Y. Dirix ◽

Jean-Paul Guastalla ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Randomized Study ◽

Metastatic Breast ◽

Phase 2 ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Amg 386 ◽

Locally Recurrent

Download Full-text